Robert J. Davie

Pharm-Olam International started operations in 1994 with the premise of delivering cost effective, quick-to-market clinical services in the emerging markets of Central and Eastern Europe. Since then, POI has expanded its services to more than 40 countries, including: North America, Western Europe, Central & Eastern Europe, Latin America, India, and South Africa. Today, POI has one of the largest global footprints of any CRO. They are committed to establishing and maintaining the industry's strongest multi-national presence. Its monitors have the most extensive knowledge of local and regional customs and sites across a broad range of therapeutic areas. POI has an entirely different model than other CROs- they call it global decentralization. The success of this model has been proven time and again.

Pharm-Olam LLC operates as a clinical research organization (CRO). It offers trial services to pharmaceutical, biotechnology, government, and public health organizations It specializes in small molecule therapies and biologics in oncology-hematology, rare disease, allergy, autoimmune, infectious disease, and vaccines. The company was founded by Zev Munk and Eugene Barg in 1994 and is headquartered in Houston, TX.

Part of CATO SMS, Pharm-Olam Group Ltd. is a clinical research organization that specializes in government-funded research. Based in Bracknell, UK, Pharm-Olam Group helps small and mid-sized biopharma companies bring new therapies to light by solving distinct challenges. The British company's Resource Center offers the latest articles, blogs, brochures, and videos from their experts. Founded in 2002, the company provides clinical expertise to ensure the success of their clients' products.